Polypeptide Group Ag · SIX:PPGN
Polypeptide — Jefferies London Healthcare Conference 2024
14 slides from Polypeptide's conference presentation, Nov 20, 2024
Slide 1: PolyPeptide Group AG
PolyPeptide Group AG Juan-José Gonzalez, CEO Jefferies London Healthcare Conference 20 November 2024 1
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Group's management in the market in which the Group Alternative Financial Performance Measures (APM) PolyPeptide Group AG (“PolyPeptide” or the “Group”). The operates. While the Group believes that such research and This Presenta
Slide 3: Peptides – one of the most attractive CDMO markets
Peptides – one of the most attractive CDMO markets Peptide drugs in clinical development (Phase I to III)1 Total 321, split by therapeutical area in % • Expect peptide therapeutics market CAGR of around 10% until 2033, driven by GLP-1 commercial launches2 27% 23% • Rich pipeline with over 800 peptid
Slide 4: The metabolic market is evolving rapidly driven by GLP-1
The metabolic market is evolving rapidly driven by GLP-1 Potential benefits beyond metabolic for large patient Continued R&D efforts and progress populations (number of patients)1 • New entrants are advancing next generation molecules Obesity ~650m Type 2 diabetes ~500m Obstructive sleep apnea >900m
Slide 5: PolyPeptide at a glance
PolyPeptide at a glance Torrance (US) Braine-l’Alleud (BE) Malmö (SE) Ambernath (IN) San Diego (US) Strasbourg (FR) • A leader in the peptide CDMO market with multisite network and over 70 years of experience • Track record of >1,000 therapeutic peptides manufactured 5
Slide 6: PolyPeptide is well positioned for accelerated growth
PolyPeptide is well positioned for accelerated growth # of active projects Reported revenue, EUR m1 268 282 320 204 Development 45% Other 64% 16% Oncology 29 For phase III 14% 39% Metabolic 64 Commercial 22% 2023 2021 2023 1 Revenue splits approximative. 6
Slide 7: PolyPeptide's growth strategy to maximize market opportunity
PolyPeptide’s growth strategy to maximize market opportunity Strategy Most innovative peptide CDMO Competitive advantages Innovation Development Modularity Multi-site network Operational / quality excellence Foundation Industrial scale capabilities Talent, culture and ESG 7
Slide 8: H1 2024 results highlight focus on execution
H1 2024 results highlight focus on execution • Operational excellence program, driving improvements in manufacturing planning and execution • Improved profitability and operating cash flow − Compared to H1 2023, EBITDA margin increased from -14.7% to +2.1% − Operating net cash flow improved from EUR
Slide 9: Investments in capacity focused on enabling GLP-1 opportunity
Investments in capacity focused on enabling GLP-1 opportunity • Completing 2021-2024 capex investment cycle of EUR ~280 m − Advancing projects across network − On track to start production ramp-up of large- scale SPPS capacity in Belgium in H2 2024 • New 2025 – 2028 capex investment cycle, focused o
Slide 10: Upgraded guidance for 2024 (communicated with H1 results)
Upgraded guidance for 2024 (communicated with H1 results) Previous New Revenue growth in % Mid to high single-digit High single-digit (vs 2023 at constant currency rates) Positive mid single-digit Profitability Positive EBITDA, EBITDA margin, operating at a net loss operating at a net loss Capital e
Slide 11: Summary and mid-term outlook
Summary and mid-term outlook • Strategy to be the most innovative peptide Double 2023 revenue by 2028 CDMO, anchored on three competitive advantages − Innovation focused on green chemistry and industrial manufacturing − Superior pipeline development EBITDA margin approaching 25% by 2028 capabilities
Slide 12: Thank you
Thank you PolyPeptide Group AG polypeptide.com 12
Slide 13: Contact and calendar
Contact and calendar Contact Events 2024 Michael Stäheli 19-20 November 2024 Jefferies Health Care conference, London Head of Investor Relations & Corporate Communications 06 December 2024 Kepler Cheuvreux GLP-1 day, Zurich T: +41 43 502 0580 E: michael.staeheli@polypeptide.com ____________ investor
Slide 14: *|% PolyPeptide
*|% PolyPeptide
PolyPeptide Group — Jefferies London Healthcare Conference 2024 on 6ix